Iambic Therapeutics, Inc. (IAM)

Iambic Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Iambic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-94.25	-77.3	-47.88
Depreciation & Amortization	1.38	1.23	1.06
Share-Based Compensation	-	2.48	1.65
Other Operating Activities	27.14	14.77	11.61
Operating Cash Flow	-65.73	-58.82	-33.56
Operating Cash Flow Growth	-	-	-

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Capital Expenditures	-2.44	-1.28	-0.71
Investing Cash Flow	-2.44	-1.28	-0.71

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Share Issuance / Repurchase	-	99.16	65.01
Debt Issued / Paid	-	-0.1	-0.02
Financing Cash Flow	153.76	99.06	64.99

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Cash Flow	85.57	38.96	30.73

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-68.17	-60.1	-34.27
Free Cash Flow Growth	-	-	-
Free Cash Flow Margin	-373.50%	-637.63%	-2869.93%